Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OccuLogix Rheo trial

This article was originally published in The Gray Sheet

Executive Summary

FDA approves an investigational device exemption for a 300-patient pivotal study of the firm's Rheo blood filtration system to treat the "dry" form of age-related macular degeneration, OccuLogix announces Jan. 29. Slated to begin this quarter, the multi-site, sham-controlled trial will evaluate vision improvement according to an acuity scale at one-year follow-up. The firm's previous trial for the device failed to meet its primary endpoint. Currently there is no FDA-approved treatment for dry AMD, which accounts for up to 90% of AMD patients, OccuLogix says...
Advertisement

Related Content

OccuLogix cuts back
Advertisement
UsernamePublicRestriction

Register

MT024462

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel